Adaptimmune Therapeutics PLC (ADAP) Given Consensus Recommendation of “Buy” by Analysts
Shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) have earned an average rating of “Buy” from the eight analysts that are presently covering the firm. Two analysts have rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $15.50.
A number of research firms recently commented on ADAP. Leerink Swann reaffirmed a “buy” rating and issued a $15.00 price target on shares of Adaptimmune Therapeutics PLC in a report on Friday, November 11th. Cowen and Company reaffirmed a “buy” rating on shares of Adaptimmune Therapeutics PLC in a report on Thursday, November 10th. Zacks Investment Research cut shares of Adaptimmune Therapeutics PLC from a “hold” rating to a “sell” rating in a report on Thursday, August 11th. Raymond James Financial Inc. began coverage on shares of Adaptimmune Therapeutics PLC in a report on Friday, September 30th. They issued an “outperform” rating and a $16.00 price target on the stock. Finally, Bank of America Corp. cut shares of Adaptimmune Therapeutics PLC from a “neutral” rating to an “underperform” rating in a report on Monday, October 24th.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) traded down 3.5874% during midday trading on Wednesday, reaching $4.9074. The company’s stock had a trading volume of 38,114 shares. Adaptimmune Therapeutics PLC has a 12 month low of $3.76 and a 12 month high of $12.85. The stock has a 50-day moving average price of $0.00 and a 200 day moving average price of $0.00.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Adage Capital Partners GP L.L.C. raised its position in Adaptimmune Therapeutics PLC by 34.8% in the second quarter. Adage Capital Partners GP L.L.C. now owns 1,550,000 shares of the company’s stock worth $12,633,000 after buying an additional 400,000 shares in the last quarter. Rathbone Brothers plc raised its position in Adaptimmune Therapeutics PLC by 124.7% in the second quarter. Rathbone Brothers plc now owns 450,525 shares of the company’s stock worth $3,672,000 after buying an additional 250,000 shares during the period. Opaleye Management Inc. purchased a new position in Adaptimmune Therapeutics PLC during the first quarter worth approximately $1,425,000. New Leaf Venture Partners L.L.C. purchased a new position in Adaptimmune Therapeutics PLC during the second quarter worth approximately $1,035,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Adaptimmune Therapeutics PLC by 7.6% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 117,234 shares of the company’s stock worth $826,000 after buying an additional 8,239 shares during the period. Institutional investors and hedge funds own 45.05% of the company’s stock.
Adaptimmune Therapeutics PLC Company Profile
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.
Receive News & Stock Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related stocks with our FREE daily email newsletter.